Moxifloxacina Rompharm (Moxifloxacin Hydrochloride)

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these targets, the drug prevents bacterial cell division, leading to a bactericidal effect that clears the infection in ocular tissues.

The dosing regimen for Moxifloxacina Rompharm is determined by the prescribing clinician based on the specific infection, severity, and patient factors. The prescriber will provide detailed instructions on the number of drops, frequency, and duration of therapy.

Safety data for Moxifloxacina Rompharm in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Moxifloxacina Rompharm belongs to the fluoroquinolone class, offering broad‑spectrum activity against Gram‑positive and Gram‑negative ocular pathogens. Compared with older agents such as ciprofloxacin, it often provides enhanced potency, better tissue penetration, and a reduced dosing frequency, though choice depends on local resistance patterns and clinician preference.

Store the product at room temperature, preferably below 25 °C, in its original container. Protect it from direct light and moisture. Do not freeze. Ensure the vial or bottle is tightly sealed when not in use to maintain sterility.

Moxifloxacina Rompharm is administered as eye drops. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and instill the prescribed number of drops into the conjunctival sac. Avoid touching the tip of the container to the eye or any surface.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, toxic anterior segment syndrome, corneal ulceration or perforation, and vision loss. Patients should be instructed to seek immediate medical attention if they experience signs of a severe reaction.

Individuals with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any component of the formulation should not use the product. Caution is also advised for patients with a history of tendon disorders, severe renal impairment, or those taking systemic fluoroquinolones without medical supervision.